Cardiovascular
drugs market covers the drugs used to treat conditions that affect the heart or
blood vessels. These conditions include heart stroke, coronary artery diseases,
valvular diseases, peripheral venous diseases, pericarditis, endocarditis,
cardiac tumors, arteriosclerosis, and lymphatic diseases.
Order report at
The global cardiovascular drugs market
has shown negative growth in the past years with a CAGR of around -1%. The year
2013 recorded highest ever market value in the 2013-2017 period, and has
fluctuated ever since, as per TBRC’s in-house consultants.
TBRC’s latest report show the historic and future trends in
the market for each year with sourced reasons to support the growth claims.
The report also shows the cardiovascular
drugs market to grow at a higher and positive CAGR by 2021 as compared
to 2017, along with geographies best suited for investments with highest return
rate.
Download report at
Anti-hypertensive
drugs was the largest segment in the cardiovascular drugs market, worth around $42
billion. This segment includes drugs such as thiazide diuretics, beta blockers,
angiotensin-converting enzyme (ace) inhibitors, calcium channel blockers, and
renin inhibitors which are used to treat hypertension. Changes in lifestyle
such as increased tobacco consumption, alcohol consumption, sedentary life,
imbalanced diet, and stress contribute to the increasing prevalence of
hypertension.
Companies included in the report
are Merck & Co., Sanofi S.A, Pfizer Inc., Bristol-Myers Squibb Company, and
Novartis AG.
The Business Research Company is a Business
Intelligence Company which excels in company, market and consumer research. It
has offices in the UK, the US and India and a network of trained researchers in
15 countries globally.
Contact
Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
No comments:
Post a Comment